| Methods |
4‐week normal sodium, placebo run‐in (week 0‐4); inclusion criteria= mean supine DBP 95‐114 mm Hg and mean daytime ambulatory DBP 90‐105 mm Hg after run‐in; 8‐week low‐sodium placebo period (week 4‐12); 12‐week double‐blind treatment (week 12‐24) |
| Participants |
Cilazapril 2.5 mg: n=19(10 males,9 females); mean age=53.7(5.7) years; baseline sitting SBP=157.3(17.1) mm Hg, DBP=104.0(8.0) mm Hg, HR=70(13) bpm;
Placebo: n=20(14 males,6 females); mean age=50.5(9.5) years; baseline sitting SBP=147.0(10.3) mm Hg, DBP=99.4(5.3) mm Hg, HR=70(10) bpm |
| Interventions |
Cilazapril 2.5 mg once daily;
Placebo;
taken before breakfast in the morning between 7 AM and 9 AM |
| Outcomes |
Trough sitting SBP/DBP using mercury sphygmomanometer;
Trough sitting HR |
| Notes |
BP change reported; SD of change not reported; 95% confidence interval of change reported; calculated SD of change from 95% CI of change; endpoint BP and SD reported; BP change data from Table 6, p. 323; endpoint BP data from Table 4, p. 322; Jadad score=3; funding source= Hoffmann‐La Roche Ltd. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
